Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Epclusa

ApprovedSmall molecule

UUniversity of Pennsylvania

Epclusa is one of 182 small molecule programs targeting Hepatitis. It is currently in Approved.

5

Indications

13

Total Trials

2

Active Trials

181

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Diabetes MellitusActive, not recruiting

Hepatitis CActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Lung TransplantationActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Diabetes MellitusApproved

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Hepatitis C Virus InfectionPhase 3

Active, not recruiting

Lung TransplantationPhase 1

Active, not recruiting

Competition

Competitive Landscape

306 competitors in Hepatitis C

#DrugCompanyPhaseTrials

Peginterferon Alfa-2

Lexapro

Epclusa

UUniversity of Pennsylvania

Victrelis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Peg-Interferon Alfa-2a

Bristol-Myers Squibb

Peginterferon Alpha-2a

Johnson & Johnson

Ledipasvir

Johnson & Johnson

Pegylated Interferon Lambda

Bristol-Myers Squibb

Paritaprevir/ritonavir/ombitasvir

Peginterferon Α-2a

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hepatitis

NCT03383419

Q4 2032

ApprovedActive, not recruiting

Diabetes Mellitus

NCT03520660

Clinical

Trials by Indication[1]

Hepatitis C3 trials

Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%

Completed·MMacfarlane Burnet Institute for Medical Research and Public Health Ltd·Phase 4·NCT05264558·606 enrolled

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

Completed·UUniversity of Pennsylvania·Phase 1/2·NCT03724149·10 enrolled

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Completed·UUniversity of Pennsylvania·Phase 2·NCT04075916·201 enrolled

Lung Transplantation2 trials

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Terminated·—·Phase 4·NCT03207399·1 enrolled

Expanding the Pool in Lung Transplantation

Completed·PPablo Sanchez·Phase 1·NCT03377478·10 enrolled

Hepatitis C Virus Infection2 trials

Micro-elimination of Hepatitis C Virus Infection in Uremics

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 3·NCT03891550·135 enrolled

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2/3·NCT02825212·10 enrolled

HCV Infection1 trial

Eliminating HCV Infection Among PWUD

Unknown status·VVancouver Infectious Diseases Centre··NCT05474781·300 enrolled

Hepatitis1 trial

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Recruiting·—·Phase 2·NCT03383419·15 enrolled

4 more indications

Acceptability1 trial

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Completed·UUniversity of California, San Francisco·Phase 4·NCT03987503·87 enrolled

Efficacy and Safety1 trial

SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University··NCT04948801·150 enrolled

Opioid1 trial

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Unknown status·SSaskatchewan Health Authority - Regina Area·Phase 4·NCT03549312·25 enrolled

Diabetes Mellitus1 trial

Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Approved·NCT03520660·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Epclusa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epclusa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epclusa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Pennsylvania

Related News